Abstract:People with Huntington's disease (HD) exhibit altered processing of emotional information, especially disgust and other negative emotions. These impairments are likely due to the effects of the disease on underlying brain networks. We examined whether oxytocin, when given intranasally, would normalise aberrant brain reactivity to emotional faces in participants with the gene-expansion for HD. In a double-blind placebo-controlled cross-over design, we measured brain activity, using functional magnetic resonance imaging, whilst nine medication-free HD carriers, and ten control participants viewed emotional (disgust, fear, angry, sad, surprise, happy) and neutral faces, following acute intranasal oxytocin (24IU) and placebo. Subjective mood changes were assessed before and after the neuroimaging on each visit. Permutation-based non-parametric statistical testing for the whole brain, showed significant group×drug interactions (p's<0.05, TFCE corrected) in areas of the left frontal pole, superior frontal, and middle frontal gyri cortically, and left putamen and thalamus sub-cortically. Parameter estimates extracted from the middle frontal gyrus and putamen showed that, under placebo, the HD group had lower brain activity to disgust stimuli, compared with controls. After intranasal oxytocin, the pattern of activation to disgust stimuli was normalised in the HD group to similar levels as controls; eight of the nine HD carriers showed increased response in the middle frontal gyrus, and seven of the nine HD carriers showed increased response in the putamen. The observed effects of oxytocin occurred in the absence of changes in subjective mood or state anxiety. These findings provide early evidence for a physiological role of oxytocin in the neuropathology of HD. Our findings are the first reported oxytocin effects in a neurodegenerative disease. Further research should examine the therapeutic benefits of oxytocin in alleviating emotional and social cognition deficits in HD and related disorders.

Oxytocin enhances group-based guilt in high moral disengagement individuals through increased moral responsibility

Oxytocin, but not vasopressin, decreases willingness to harm others by promoting moral emotions of guilt and shame

Oxytocin modulates third-party sanctioning of selfish and generous behavior within and between groups

Oxytocin Facilitates Self-Serving Rather Than Altruistic Tendencies in Competitive Social Interactions Via Orbitofrontal Cortex

Opposing Oxytocin Effects on Intergroup Cooperative Behavior in Intuitive and Reflective Minds

Oxytocin salvages context-specific hyperaltruistic preference through moral framing

The Effect of Oxytocin on Third-Party Altruistic Decisions in Unfair Situations: An fMRI Study

Would you? Effects of oxytocin on moral choices in forensic psychopathic patients

The effect of oxytocin on group formation and strategic thinking in men

The association of oxytocin with major depressive disorder: role of confounding effects of antidepressants

Intranasal oxytocin interacts with testosterone reactivity to modulate parochial altruism

Oxytocin Modulates Social Value Representations in the Amygdala

Intranasal administration of oxytocin increases human aggressive behavior

Oxytocin Alters the Effect of Payoff but Not Base Rate in Emotion Perception.

The OXTR Rs53576 Impacts Moral Permissibility of Attempted but Failed Harms in Populations of Students and Prisoners

Why does advantageous inequity promote prosocial behavior? The roles of justice sensitivity and guilt

Oxytocin Modulates the Racial Bias in Neural Responses to Others' Suffering.

Guilt Leads to Enhanced Facing-the-viewer Bias

Oxytocin Facilitation of Emotional Empathy Is Associated With Increased Eye Gaze Toward the Faces of Individuals in Emotional Contexts

Oxytocin differentially modulates reward system responses to social and non-social incentives

Oxytocin selectively modulates brain processing of disgust in Huntington's disease gene carriers